Wednesday, July 8, 2026

pharma · Multiple Myeloma · generalized myasthenia gravis · RNAC

Cartesian Therapeutics

Cartesian Therapeutics is a pharma organization headquartered in Frederick, USA. It trades on NYSE under ticker RNAC. Primary therapeutic focus areas include Multiple Myeloma, generalized myasthenia gravis, Myasthaenia G

7495 New Horizon Way, Frederick, Maryland 21703, US HQ
2016 Founded
89 Employees
Public company Type
RNAC · NYSE Ticker
Company details
Status
Public
HQ
7495 New Horizon Way, Frederick, Maryland 21703, US
Founded
2016
Employees
89
Programs
12
Drugs
4
Patents
4
Clinical program

Descartes-08

Phase 2 · small molecule · Myasthenia Gravis, Generalized

Descartes-08 for Myasthenia Gravis, Generalized is a Phase 2 program (small_molecule) at Cartesian Therapeutics with 1 ClinicalTrials.gov record(s).

← All Cartesian Therapeutics projects Phase 2 small molecule active

Internal code MG-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Cartesian Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Myasthenia Gravis, Generalized
Status
active
Trials
1

Clinical trials